Oncolines B.V.

Oncolines B.V. (Oss, The Netherlands) is a precision medicine services company in oncology and cancer immunotherapy, part of Symeres B.V. (Nijmegen, The Netherlands). We help to bring improved and novel therapies to the right patient population faster.

Our clients are clinical and preclinical biopharmaceutical companies that seek differentiation for their drugs and drug candidates. We offer a set of complimentary services to enable our clients to characterize their compounds, determine activities, selectivities and mechanism of action. We present results in a unique interactive reporting format that facilitates easier and faster interpretation of results.

Oncolines Profiling is the parallel dose-response testing of compounds on a large panel of genetically characterized human cancer cell lines. We analyze the correlation and mutation status of more than 100 cancer genes, to identify drug response biomarkers for selecting the right patient population for clinical trials.

SynergyFinder is the profiling of combinations of drugs, to identify new synergistic drug combinations.

We perform gene and protein expression analysis, DNA and RNA sequencing, and flow cytometry, to investigate the mechanism of action of drug candidates.

ResidenceTimer is the determination of binding kinetics of compound - target interactions. We have more than 100 kinase assays available.

QuickScout is kinase inhibitor profiling in enzyme activity assays at Carna Biosciences, Inc. (Kobe, Japan). We represent Carna in Europe and Israel. 326 wild-type and mutant kinases are available for profiling (% effect and IC50) at Carna.